Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip R Greipp

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood|January 24, 2004
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyAngela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Mayo Clinic Proceedings|February 3, 2009
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative componentJohn A Lust, Martha Q Lacy, Steven R Zeldenrust, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Blood|December 17, 2009
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patientsFrancesca Gay, Suzanne R Hayman, Martha Q Lacy, et al.
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Blood|January 24, 2004
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control studyAngela Dispenzieri, Robert A Kyle, Martha Q Lacy, et al.
Pageof 12